MIRACLE: A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse
Study Details
Study Description
Brief Summary
Early-stage non small cell lung cancer represents 20-30% of all non small cell lung cancer and is characterized by a high survival probability after surgical resection. However, considering stage IA-IIIA non small cell lung cancer, a relapse rate of about 50% is observed, with a different survival probability on the basis of tumor node metastasis status, although patients within the same tumor node metastasis stage exhibit wide variations in recurrence rate. There are currently no validated prognostic biomarkers able to identify patients with a high risk of relapse.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
This study will use data from an already available cohort of patients enrolled in the Resting study (a project funded by TRANSCAN in 2018) as a training set and data from a new concurrent cohort as validation set.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Resected early stage non small cell lung cancer Early stage (IA-IIIA) resectable non small cell lung cancer patients receiving surgery |
Other: Resected non small cell lung cancer
plasma sample, tissue sample and computed tomography scan images
|
Outcome Measures
Primary Outcome Measures
- Algorithm for disease free survival [18 months]
Analysis on a training cohort of resected early-stage non small cell lung cancer
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient with an early stage of non small cell lung cancer
-
Indication of surgical resection
-
Patient able to understand and give his consent
-
Patient affiliated to the health insurance
Exclusion Criteria:
-
Patient with another cancer in the last 5 years
-
Patient with an allergy to the contrast medium
-
Patient under legal protection
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Julien MAZIERES | Toulouse | France | 31059 |
Sponsors and Collaborators
- University Hospital, Toulouse
Investigators
- Principal Investigator: Julien MAZIERES, MD, PhD, University Hospital, Toulouse
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RC31/21/0519